Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

54.63 +0.27 (+0.50%)
Official Closing Price Updated: 4:15 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
3 Cathie Wood Stocks to Buy Now: May 2024
Many popular stocks are down, but it may be a mistake to discount these Cathie Wood stocks to buy as new catalysts come to be. 
Via InvestorPlace
ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
Sanofi collaborates with OpenAI and Formation Bio to enhance drug development. The partnership leverages proprietary data, advanced AI models, and engineering expertise to accelerate the biopharma... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Stocks, Gold Reach New Record Highs, Cruise Stocks Rally, GameStop Sinks: What's Driving Markets Monday?
Wall Street rallies on Monday as major US indices reach fresh record highs. Metal commodities surge, Treasury yields stay stable. Cruise stocks soar. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Check Out What Whales Are Doing With MRNA
Via Benzinga
Smart Money Is Betting Big In MRNA Options
Via Benzinga
Is This a Setback for Moderna?
Moderna's shares slipped after the company announced the delay. 
Via The Motley Fool
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Could Novavax Become the Next Moderna?
Sanofi believes in Novavax's vaccine strengths... 
Via The Motley Fool
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
Jim Cramer: This Industrial Company Is 'Absolutely Terrific', Recommends Buying Modine Manufacturing
Regarding Hertz, Jim Cramer said, "I don't want you to sell, and I don't want you to double down. Let's just see if it can't go higher." 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $500 Today
Via Benzinga
Moderna to Present at Upcoming Conferences in May/June 2024
Via ACCESSWIRE
Moderna Announces Update on Investigational RSV Vaccine
Via ACCESSWIRE
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
As 'Roaring Kitty' Returns, Here Are 3 ETFs To Leverage The 2024 Meme Stock Wave
Meme stocks, led by Keith Gill, have resurfaced on social media, causing GameStop's stock to surge by 74% and AMC's by 80%. ETFs like ARCA:STCE can capitalize on this trend. 
Via Benzinga
Topics ETFs
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Patience often pays off in the equity markets. 
Via The Motley Fool
Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?
This team-up is more than a PR stunt, but it might not be revolutionary. 
Via The Motley Fool
The 10 Worst Performing S&P 500 Stocks in 2023 - Are They Good Investments Now?
A look at the 10 worst-performing S&P 500 stocks in 2023. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures. 
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported. 
Via Benzinga
Exposures Product Safety
Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine
The FDA hasn't said there are any vaccine effectiveness, safety or quality issues that would prevent approval, Moderna says. 
Via Investor's Business Daily
Exposures Product Safety
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. 
Via MarketBeat
Topics ETFs
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
The COVID-19 pandemic thrust this company's science -- and its stock -- into the spotlight. 
Via The Motley Fool
Exposures COVID-19
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios. 
Via InvestorPlace
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.